ASO targeting RBM3 temperature-controlled poison exon splicing prevents neurodegeneration in vivo.
Level 5 - mechanism / opinion, no new human data
Preclinical animal and bench research
PubMed 36946385 · doi:10.15252/emmm.202217157
What was done
Researchers identified a temperature-sensitive poison exon within the RBM3 gene responsible for cold-induced expression of the cold-shock protein RBM3. They evaluated whether genetic removal or antisense oligonucleotide (ASO)-mediated exclusion of this exon (using FDA-approved chemistry) could upregulate RBM3 at normothermia in mouse brains and tested neuroprotection following a single ASO dose in prion-diseased mice.
What was found
Targeting the poison exon via genetic deletion or ASO administration resulted in sustained upregulation of RBM3 expression in mouse brains without hypothermia. In prion-diseased mice, a single ASO treatment prevented neuronal loss and spongiosis despite high levels of disease-associated prion protein. The abstract reports no numerical values or statistical metrics.
Why it matters
Therapeutic hypothermia provides neuroprotection through RBM3 but entails severe systemic risks; targeting poison exon splicing offers a normothermic pharmacological approach to leverage this pathway using translatable ASO chemistry.
Limits
The study is limited entirely to preclinical animal (mouse) and in vitro models, lacking human data. No sample sizes, quantitative effect sizes, duration metrics, or off-target safety profiles are reported in the abstract.
Cited by
- supports Hibernating mammals lose 30% to 40% of their neuronal synapses during hibernation and regrow them upon waking via upregulation of the cold-shock gene RBM3.